Capasso A, Di Giannuario A, Loizzo A, Pieretti S, Sagratella S, Sorrentino L
School of Pharmacy, University of Salerno, Italy.
J Pharmacol Exp Ther. 1996 Feb;276(2):743-51.
The effect of dexamethasone on acute opiate withdrawal induced by mu, kappa and delta receptor agonists was investigated in vitro. After a 4-min in vitro exposure to morphine (less selective mu agonist), D-Ala2-N-methyl-Phe4-Gly5-ol)-enkephalin (DAGO; highly selective mu agonist) and trans(+/-)-3,4-dichloro-N-methyl-N-[2(1-pyrrolidynyl)cyclohexyl]- benzeneacetamide (U50-488H; highly selective kappa agonist) a strong contracture of guinea pig isolated ileum was observed after the addition of naloxone. This effect was also observed when rabbit isolated jejunum was pretreated with deltorphin (highly selective delta agonist). Dexamethasone treatment before or after the opioid agonists tested was capable of both preventing and reverting the naloxone-induced contracture after exposure to mu opiate agonists morphine and DAGO in a concentration- and time-dependent fashion. Also, the steroid reduced naloxone-induced contracture after the exposure to U50-488H only when injected before the kappa opiate agonist. Finally, it did not affect the naloxone contracture after exposure to deltorphin. Pretreatment with RU-38486, a glucocorticoid receptor antagonist, inhibited dexamethasone antagonism on responses to both mu and kappa agonists, whereas pretreatment with cycloheximide, a protein synthesis inhibitor, blocked only the antagonistic effects of dexamethasone on responses to the mu opioid agonists. Overall, these data indicate that dexamethasone induces significant effects on mu-mediated opiate with-drawal in vitro, which suggest an important functional interaction between corticosteroids and the opioid system primarily at the mu receptor level. The ability of RU-38486 and cycloheximide to block dexamethasone effects indicates that the steroid interference on mu-mediated withdrawal involves a protein synthesis-dependent mechanism via glucocorticoid receptor.
在体外研究了地塞米松对由μ、κ和δ受体激动剂诱导的急性阿片戒断的影响。在体外将豚鼠离体回肠暴露于吗啡(选择性较低的μ激动剂)、D-Ala2-N-甲基-Phe4-Gly5-ol)-脑啡肽(DAGO;高选择性μ激动剂)和反式(+/-)-3,4-二氯-N-甲基-N-[2(1-吡咯烷基)环己基]-苯乙酰胺(U50-488H;高选择性κ激动剂)4分钟后,加入纳洛酮后观察到豚鼠离体回肠强烈收缩。当兔离体空肠用强啡肽(高选择性δ激动剂)预处理时也观察到这种效应。在测试的阿片类激动剂之前或之后进行地塞米松处理,能够以浓度和时间依赖性方式预防和逆转暴露于μ阿片类激动剂吗啡和DAGO后纳洛酮诱导的收缩。此外,仅在κ阿片类激动剂之前注射时,该类固醇可降低暴露于U50-488H后纳洛酮诱导的收缩。最后,它不影响暴露于强啡肽后纳洛酮引起的收缩。用糖皮质激素受体拮抗剂RU-38486预处理可抑制地塞米松对μ和κ激动剂反应的拮抗作用,而用蛋白质合成抑制剂环己酰亚胺预处理仅阻断地塞米松对μ阿片类激动剂反应的拮抗作用。总体而言,这些数据表明地塞米松在体外对μ介导的阿片戒断有显著影响,这表明皮质类固醇与阿片系统之间主要在μ受体水平存在重要的功能相互作用。RU-38486和环己酰亚胺阻断地塞米松作用的能力表明,类固醇对μ介导的戒断的干扰涉及通过糖皮质激素受体的蛋白质合成依赖性机制。